VT-5006 / Vertero Therapeutics - LARVOL DELTA

Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease (The Manila Times) - "The Phase 1a portion of the study is enrolling healthy volunteers to receive VT-5006 either as a single dose or once daily for seven days."

Trial status • Parkinson's Disease

DEVELOPMENT OF AX-5006, A SMALL MOLECULE INHIBITOR OF CSGA AGGREGATION AS A POTENTIAL DISEASE-MODIFYING TREATMENT FOR PARKINSON'S DISEASE (ADPD 2024) - "AX-5006 is a small molecule inhibitor of bacterial CsgA aggregation in the gut. Efficacy data in the ASO mouse model as well as its pharmacokinetic profile support AX-5006 as a novel development candidate. IND-enabling nonclinical studies are underway, and a clinical study is anticipated to begin in 2024."

CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease (GlobeNewswire) - "The funding will support further preclinical development to assess the therapeutic efficacy of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of disease in Parkinson’s disease (PD). IND-enabling studies of AX-5006 are ongoing to support initiation of a Phase 1 clinical trial in 2024."

Financing • New P1 trial • CNS Disorders • Parkinson's Disease